Long-Term Effects of Adding Exenatide to a Regimen of Metformin and/or Sulfonylurea in Type 2 Diabetes: An Uncontrolled, Open-Label Trial in Hungary

The findings from this open-label, single-arm study characterized the response to exenatide 10 μg BID for up to 132 weeks. Significant, persistent improvements in HbA1c and weight were observed in patients receiving exenatide BID, with reported AEs consistent with those from studies of shorter duration. ClinicalTrials.gov identifier: NCT00044668.